Technical Analysis for TTPH - Tetraphase Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 0.7959 2.18% 0.02
TTPH closed up 2.18 percent on Friday, May 24, 2019, on 54 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical TTPH trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 2.18%
Wide Bands Range Expansion 2.18%
Oversold Stochastic Weakness 2.18%
1,2,3 Retracement Bearish Bearish Swing Setup -2.94%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.94%
Lower Bollinger Band Walk Weakness -2.94%
Wide Bands Range Expansion -2.94%

Older signals for TTPH ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various antibiotics for the treatment of serious and life-threatening multi-drug resistant infections through its chemistry technology. Its principal products include eravacycline, an intravenous and oral antibiotic that use as a empiric monotherapy has completed the Phase II clinical trials for the treatment of multi-drug resistant Gram-negative infections; and eravacycline oral formulation that is in Phase I clinical trials to treat complicated urinary tract infections in intravenous-to-oral step-down therapy. The company's products that are under development comprise TP-834; and TP-271 that is in preclinical trials for the treatment of respiratory diseases caused by bacterial biothreat pathogens, as well as engages in the development of Pseudomonas/Gram-negative program. Tetraphase Pharmaceuticals, Inc. was founded in 2006 and is based in Watertown, Massachusetts.
Medicine Chemistry Pharmacology Antibiotics Multiple Drug Resistance Pyrrolidines Respiratory Diseases Pseudomonas Carbapenem Basilea Pharmaceutica Eravacycline Multi Drug Resistant Gram Negative Infections
Is TTPH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 4.49
52 Week Low 0.75
Average Volume 568,022
200-Day Moving Average 1.7891
50-Day Moving Average 1.1049
20-Day Moving Average 0.9382
10-Day Moving Average 0.8354
Average True Range 0.0766
ADX 37.48
+DI 9.2377
-DI 24.951
Chandelier Exit (Long, 3 ATRs ) 0.8802
Chandelier Exit (Short, 3 ATRs ) 0.9798
Upper Bollinger Band 1.1571
Lower Bollinger Band 0.7193
Percent B (%b) 0.17
BandWidth 46.663824
MACD Line -0.0905
MACD Signal Line -0.0814
MACD Histogram -0.0091
Fundamentals Value
Market Cap 40.63 Million
Num Shares 51.1 Million
EPS -2.82
Price-to-Earnings (P/E) Ratio -0.28
Price-to-Sales 58.89
Price-to-Book 2.16
PEG Ratio -0.01
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.86
Resistance 3 (R3) 0.86 0.84 0.85
Resistance 2 (R2) 0.84 0.82 0.84 0.85
Resistance 1 (R1) 0.82 0.81 0.81 0.82 0.85
Pivot Point 0.80 0.80 0.79 0.80 0.80
Support 1 (S1) 0.77 0.78 0.76 0.77 0.75
Support 2 (S2) 0.75 0.77 0.75 0.74
Support 3 (S3) 0.73 0.75 0.74
Support 4 (S4) 0.73